Latest & greatest articles for alzheimer's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alzheimer's disease

1. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials Full Text available with Trip Pro

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) Psychiatry Actions . 2020 Jul 20;jnnp-2019-321913. doi: 10.1136/jnnp-2019-321913. Online ahead of print. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials # , # , # , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China jintai_yu

2020 EvidenceUpdates

2. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial Full Text available with Trip Pro

in beta-amyloid protein–infused rats. J Neurochem. 1996;66(3):1113-1117. doi:10.1046/j.1471-4159.1996.66031113.x - - Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease. Mov Disord. 1997;12(6):885-897. doi:10.1002/mds.870120609 - - Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors (...) Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID

2020 EvidenceUpdates

3. Flortaucipir F18 (Tauvid) - Diagnostic agent for patients with Alzheimer’s disease

Flortaucipir F18 (Tauvid) - Diagnostic agent for patients with Alzheimer’s disease Drug Approval Package: TAUVID U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TAUVID Company: Avid Radiopharmaceuticals, Inc. Application Number: 212123 Approval Date: 05/28/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

4. Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT Full Text available with Trip Pro

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer's disease over 2 years and minocycline 400 mg was poorly tolerated. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Robert Howard 1, * , Olga Zubko 2 , Richard Gray 3 , Rosie Bradley 4 , Emma Harper 4 , Linda Kelly 4 , Lynn Pank 4 , John O’Brien 5 , Chris Fox 6 , Naji Tabet 7 , Gill

2020 NIHR HTA programme

5. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. Full Text available with Trip Pro

Cognitive symptoms of Alzheimer's disease: clinical management and prevention. Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid β in the form of extracellular plaques and by intracellular neurofibrillary tangles, with eventual neurodegeneration and dementia. There is currently no disease-modifying treatment though several symptomatic medications exist with modest benefit on cognition. Acetylcholinesterase inhibitors have (...) promising disease-modifying interventions, mostly addressing the amyloid cascade hypothesis of AD, have recently failed to demonstrate efficacy so novel approaches must be considered.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

6. A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease

studies pointed out that a “bidirectional relationship” exists between the two diseases and must be considered. Patients with AD typically do not possess the cognitive or physical ability to perform proper oral hygiene, therefore predisposing them to periodontal disease. Applicability Due to the increasing life expectancy of our patients and chronic nature of both periodontal and Alzheimer’s disease, dental providers will be confronted with both conditions. Therefore, it is imperative that we (...) A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease UTCAT3403, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease Clinical Question Is a patient with periodontal disease at higher risk of developing Alzheimer’s disease, compared to an individual without periodontal disease? Clinical Bottom Line

2019 UTHSCSA Dental School CAT Library

7. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. Full Text available with Trip Pro

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources

2019 Cochrane

8. Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial (Abstract)

Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial Our study aimed to assess the effect of a 12-month vitamin D supplementation on cognitive function and amyloid beta (Aβ)-related biomarkers in subjects with Alzheimer's disease (AD). METHODS : This was a randomised, double-blind, placebo-controlled trial. 210 AD patients were randomly divided

2019 EvidenceUpdates

9. ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors Jill S. Goldman, MS, MPhil 1,2 , Susan E. Hahn, MS 3 , Jennifer Williamson Catania, MS, MPH 1,2 , Susan LaRusse-Eckert, MS 2 , Melissa (...) the following considerations in reaffirming this document: 1. To use the phrase “pathogenic variant” rather than the word “mutation” in discussing pathogenic variants related to autosomal dominant early-onset Alzheimer disease. This would be consistent with current ACMG/AMP Guidelines for Variant Interpretation and Reporting 1 . 2. Because this document no longer meets the criteria for an evidence-based practice guideline by either the American College of Medical Genetics and Genomics (ACMG) or National

2019 American College of Medical Genetics and Genomics

10. Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow

Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Prescrire IN ENGLISH - Spotlight ''Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow'', 1 May 2019 {1} {1} {1} | | > > > Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow A study conducted by the independent French medical journal Prescrire shows a reduction of only around 26% in the number of patients in France exposed to at least one Alzheimer's disease drug between 2012 and 2017. In approximately 3 out of 4 newly exposed patients, treatment lasted for more than 6 months, despite the proven harms. In France, as far back as 2011, the pharmacoeconomic committee

2019 Prescrire

11. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease Full Text available with Trip Pro

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened (...) carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score

2019 EvidenceUpdates

12. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Full Text available with Trip Pro

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due (...) to Alzheimer's disease.We conducted a randomized, double-blind, placebo-controlled, 104-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia. The primary outcome was the change from baseline to week 104 in the score on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores

2019 NEJM Controlled trial quality: predicted high

13. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. Full Text available with Trip Pro

, and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60 (...) Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.Nationwide case-control study.Finnish national population and drug register, between 1999 and 2013.All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician

2019 BMJ

14. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Heterogeneity of outcomes in Alzheimer's disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE) ε4 genotype, family history of AD, and amyloid abnormalities.Modeling estimated the number of randomized patients needed to detect a 2-point

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

15. Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Full Text available with Trip Pro

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Preliminary studies have shown that treatment with plasma exchange (PE) plus therapeutic albumin replacement in patients with Alzheimer's disease (AD) induced mobilization of plasma and cerebrospinal fluid amyloid β protein, associated with an improvement in memory and language functions, as well as the stabilization of brain perfusion, which persisted after treatment

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

16. Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease. Full Text available with Trip Pro

Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease. Animal models of Alzheimer's disease show that exercise may modify β-amyloid (Aβ) deposition. We examined the effect of a 16-week exercise intervention on cortical Aβ in patients with mild-to-moderate Alzheimer's disease.Thirty-six patients with Alzheimer's disease were randomized to either one hour of aerobic exercise three times weekly for 16 weeks or usual care. Pre and post intervention

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

17. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Full Text available with Trip Pro

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive impairment. This long preclinical period provides an opportunity for clinical trials designed to prevent or delay the onset of cognitive impairment due to AD. Under (...) the umbrella of the Alzheimer's Prevention Initiative Generation Program, therapies targeting Aβ, including CNP520 (umibecestat), a β-site-amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor, and CAD106, an active Aβ immunotherapy, are in clinical development in preclinical AD.The Alzheimer's Prevention Initiative Generation Program comprises two pivotal (phase 2/3) studies that assess the efficacy and safety of umibecestat and CAD106 in cognitively unimpaired individuals with high risk

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

18. Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. Full Text available with Trip Pro

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy as measured by volumetric magnetic resonance imaging (MRI).In the EXPEDITION3 phase 3 trial (...) , participants with mild Alzheimer's disease were randomized to receive intravenous infusions of either 400 mg of solanezumab or placebo every 4 weeks for 76 weeks. Volumetric MRI scans were acquired at baseline and at 80 weeks from 275 MRI facilities using a standardized imaging protocol. A subset of 1462 patients who completed both MRI and 14-item Alzheimer's Disease Assessment Scale-Cognitive Subscale assessments at both time points were selected for analysis. Longitudinal MRI volume changes were analyzed

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

19. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. Full Text available with Trip Pro

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. S47445 is a novel positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors that may emerge as a favorable candidate for the symptomatic treatment of cognitive and depressive disorders in patients suffering from Alzheimer's disease (AD) of mild to moderate severity (...) and with depressive symptoms.For this double-blind, placebo-controlled 24-week phase II trial, 520 outpatients aged between 55 and 85 years, with probable AD at mild to moderate stages (a Mini-Mental State Examination score of 24-15 inclusive) and exhibiting depressive symptoms (Cornell Scale for Depression in Dementia [CSDD] ≥ 8) were recruited in twelve countries and randomized to 3 doses of S47445 (5-15-50 mg) or placebo. The primary end point was the change from baseline in the 11-item Alzheimer's Disease

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: predicted high

20. Treatment of epilepsy for people with Alzheimer's disease. Full Text available with Trip Pro

Treatment of epilepsy for people with Alzheimer's disease. Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of these treatments; this review aims to review those different modalities. This is an updated version

2018 Cochrane